BRIEF—Genmab fills newly-created post of COO

Danish biotech Genmab says that Anthony Mancini will join the company on March 23 as executive vice president and chief operating officer, a newly-created position.

Mr Mancini will be responsible for overseeing Genmab’s commercial, corporate development, business development and information technology functions, and join the executive team of chief executive Dr Jan van de Winkel.

Mr Mancini’s responsibilities will include the successful direction, planning, and execution of all aspects of Genmab’s commercial strategies and the further optimization of the organization to achieve its inspirational vision of transforming cancer treatment and bringing its own differentiated therapeutic products to the market.

Mr Mancini brings to Genmab strategic and operational leadership as well as a consistent track record of growth across North America, Europe and Australia. He has held positions of increasing responsibility in sales, marketing and general management; leading launches and alliances across various therapeutic areas including oncology, hematology, cardiovascular, immunology, metabolic disease, and virology. Most recently, he led Bristol-Myers Squibb’s (NYSE: BMY) US Innovative Medicines Unit, a team of over 1,100 people focused on immunology and cardiovascular diseases.

Mr Mancini will be based in Princeton, New Jersey, USA, whilst traveling regularly to Genmab’s other sites in Copenhagen, Denmark, Utrecht, The Netherlands, and Tokyo, Japan.